Who
Frank Pasqualone
Director
Company insider
Files Form 4 as: Director, Enveric Biosciences; SVP, Chief Business Officer, Theravance Biopharma; Sr. Vice President, Operations, Innoviva.
In numbers
- Trades disclosed
- 40
- Buys
- 2
- Sells
- 0
- Bought
- $108K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 23 Jan 2014
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | ENVB Enveric BiosciencesBiotechnology | SEC FORM 4 Code A | —18,518 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ENVB Enveric BiosciencesBiotechnology | SEC FORM 4 Code A | —18,518 at $0.00 | filing |
| 23 Dec 2025filed 30 Dec 2025 | ENVB Enveric BiosciencesBiotechnology | SEC FORM 4 Code A | —7,633 at $0.00 | filing |
| 9 Oct 2024filed 11 Oct 2024 | ENVB Enveric BiosciencesBiotechnology | SEC FORM 4 Code A | —47,733 at $0.00 | filing |
| 15 Sep 2023filed 19 Sep 2023 | ENVB Enveric BiosciencesBiotechnology | SEC FORM 4 Bought | $2,1401,000 at $2.14 | filing |
| 19 Nov 2021filed 23 Nov 2021 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $32K3,779 at $8.36 | filing |
| 20 Aug 2021filed 24 Aug 2021 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $53K3,779 at $14.05 | filing |
| 20 May 2021filed 24 May 2021 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $67K3,779 at $17.80 | filing |
| 20 Feb 2021filed 23 Feb 2021 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $507K26,961 at $18.79 | filing |
| 8 Feb 2021filed 10 Feb 2021 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 20 Nov 2020filed 24 Nov 2020 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $73K4,214 at $17.21 | filing |
| 20 Aug 2020filed 24 Aug 2020 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $77K4,214 at $18.22 | filing |
| 20 May 2020filed 22 May 2020 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $112K4,214 at $26.67 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $632K24,392 at $25.90 | filing |
| 3 Feb 2020filed 5 Feb 2020 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 3 Feb 2020filed 5 Feb 2020 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —54,000 at $0.00 | filing |
| 20 Nov 2019filed 22 Nov 2019 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $43K2,447 at $17.60 | filing |
| 20 Aug 2019filed 22 Aug 2019 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $50K2,335 at $21.51 | filing |
| 20 May 2019filed 22 May 2019 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $32K1,604 at $19.84 | filing |
| 20 Feb 2019filed 22 Feb 2019 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $133K4,919 at $27.00 | filing |
News
Enveric Biosciences Moves Lead Neuroplastogenic Candidate Closer To Clinical TestingENVB · rttnews.com · 22 Oct 2026
0 headlines in the last 90 days name Frank Pasqualone; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.